ストックスクリーナーアプリを入手
186.36
5.36%
-10.55
アフターアワーズ：
194.00
7.64
+4.10%
前日終値:
$196.91
開ける：
$197.61
24時間の取引高:
2.23M
Relative Volume:
1.68
時価総額：
$26.69B
収益：
$2.50B
当期純損益:
$-226.32M
株価収益率:
-113.55
EPS:
-1.6412
ネットキャッシュフロー:
$71.51M
1週間 パフォーマンス:
-4.06%
1か月 パフォーマンス:
-10.05%
6か月 パフォーマンス:
-8.77%
1年 パフォーマンス:
+24.74%
1日の値動き範囲:
$184.81
$198.65
1週間の範囲:
$184.81
$206.00
52週間の値動き範囲:
$131.81
$256.36
Natera Inc Stock (NTRA) Company Profile
Compare NTRA vs TMO, DHR, IDXX, WAT, A
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
186.36 | 28.20B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-14 | 開始されました | William Blair | Outperform |
| 2026-01-07 | 開始されました | Citigroup | Buy |
| 2025-12-02 | 再開されました | Morgan Stanley | Overweight |
| 2025-10-27 | アップグレード | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | 再開されました | Wells Fargo | Equal Weight |
| 2025-03-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-01-23 | 開始されました | Barclays | Overweight |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-08 | 再開されました | Craig Hallum | Buy |
| 2024-02-20 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | 繰り返されました | BTIG Research | Buy |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-11-13 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | 開始されました | Bernstein | Mkt Perform |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-05-05 | 開始されました | UBS | Buy |
| 2023-01-18 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-04-25 | 開始されました | Stephens | Overweight |
| 2022-03-08 | 開始されました | Goldman | Buy |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-06-15 | 開始されました | Raymond James | Mkt Perform |
| 2021-05-25 | 開始されました | Wells Fargo | Overweight |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-10-08 | 開始されました | BTIG Research | Buy |
| 2020-09-28 | 開始されました | Morgan Stanley | Overweight |
| 2020-09-17 | 開始されました | SVB Leerink | Outperform |
| 2020-06-10 | 再開されました | Piper Sandler | Overweight |
| 2020-05-07 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-10-05 | 開始されました | JP Morgan | Neutral |
| 2018-07-05 | 繰り返されました | Piper Jaffray | Overweight |
| 2017-08-07 | 繰り返されました | Morgan Stanley | Overweight |
| 2016-11-10 | 繰り返されました | The Benchmark Company | Buy |
| 2016-05-23 | 繰り返されました | The Benchmark Company | Buy |
| 2016-05-11 | 繰り返されました | The Benchmark Company | Buy |
| 2016-04-19 | 開始されました | The Benchmark Company | Buy |
| 2015-09-28 | アップグレード | Wedbush | Neutral → Outperform |
| 2015-08-14 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | 開始されました | Robert W. Baird | Outperform |
| 2015-07-27 | 開始されました | Morgan Stanley | Equal-Weight |
| 2015-07-27 | 開始されました | Piper Jaffray | Overweight |
| 2015-07-27 | 開始されました | Wedbush | Neutral |
すべてを表示
Natera Inc (NTRA) 最新ニュース
Natera Inc stock (US6323071042): insider selling and a sharp pullback unsettle investors - AD HOC NEWS
Natera Scores Rare FDA Approval but Shares Drop - TechStock²
Natera co-founder Sheena Jonathan sells $959,450 in company stock - Investing.com
Natera (NTRA) co-founder Jonathan Sheena sells 4,650 shares under 10b5-1 plans - Stock Titan
New blood test helps tailor bladder cancer treatment, wins FDA backing - Stock Titan
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod - Fierce Pharma
Natera's Signatera CDx Approved by FDA as Companion Diagnostic in Muscle-Invasive Bladder Cancer - Moomoo
Natera Gets FDA Approval for Bladder-Cancer Test - marketscreener.com
Signatera CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC) - Business Wire
NTRA Technical Analysis | Trend, Signals & Chart Patterns | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera’s Stronghold in Cancer Recurrence Tests Prompts Wood’s Ark to Expand Stake - The Daily Upside
(NTRA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Natera, Inc.Common Stock (NQ: NTRA - FinancialContent
Natera NTRA Q1 2026 Earnings Call Transcript - AOL.com
The Cancer Test That Wall Street Is Betting On - Mint
5 Must-Read Analyst Questions From Natera’s Q1 Earnings Call - The Globe and Mail
Natera (NTRA) Sees Recent Investment Surge from ARK Investment - GuruFocus
Cathie Wood’s ARK sells Twist Bioscience, buys Natera stock - Investing.com
Cathie Wood’s ARK sells Twist Bioscience, buys Natera stock By Investing.com - Investing.com Australia
Analysts Have Made A Financial Statement On Natera, Inc.'s (NASDAQ:NTRA) First-Quarter Report - simplywall.st
Natera, Inc. (NASDAQ:NTRA) Just Released Its First-Quarter Earnings: Here's What Analysts Think - Moomoo
Why Natera (NTRA) Shares Are Plunging Today - Yahoo Finance
Natera price target raised to $249 from $240 at Piper Sandler - TipRanks
Why Natera (NTRA) Is Down 5.9% After Raising 2026 Guidance But Posting a Wider Q1 Loss - simplywall.st
NTRA Stock Price, Quote & Chart | NATERA INC (NASDAQ:NTRA) - ChartMill
NTRA Q1 Deep Dive: Robust Volume Growth and Product Expansion Shape Outlook - Yahoo Finance
Number of shareholders of Natera, Inc. – BX:NTRA - TradingView
Earnings call transcript: Natera Inc. sees mixed Q1 2026 results; stock drops By Investing.com - Investing.com Australia
NTRA Maintained by BTIG -- Price Target Lowered to $250 - GuruFocus
Earnings call transcript: Natera Inc. sees mixed Q1 2026 results; stock drops - Investing.com
Natera stock price target lowered to $250 by BTIG on valuation - Investing.com Nigeria
Assessing Natera (NTRA) Valuation After Recent Share Price Pullback And Long Term Returns - Yahoo Finance
Assessing Natera (NTRA) Valuation After Record Q1 Growth And Ongoing Profitability Concerns - simplywall.st
Natera (NTRA) Is Up 6.6% After Record Q1 Revenue But Wider LossesHas The Bull Case Changed? - Yahoo Finance
Natera Lifts 2026 Outlook As Test Volumes Climb And Japan Entry Nears - Sahm
Natera (NTRA) Q4 Profit Of US$47.3 Million Tests Longstanding Loss‑Making Narrative - Sahm
Natera Stock To $136? - Trefis
Natera Q1 2026 slides: revenue jumps 39%, guidance raised By Investing.com - Investing.com South Africa
Natera’s Earnings Call Signals Strong Growth Momentum - TipRanks
NTRA Maintained by JP Morgan -- Price Target Raised to $265 - GuruFocus
Natera Price Target Raised to $220.00/Share From $215.00 by Wells Fargo - Moomoo
Natera (NTRA) Eps Diluted (TTM) - Zacks Investment Research
NTRA Maintained by Evercore ISI Group -- Price Target Raised to $270 - GuruFocus
NTRA Maintained by Wells Fargo -- Price Target Raised to $220 - GuruFocus
Natera, Inc. Stock 12‑Month Price Target Raised to $260.78, Implies 19% Upside - TradingView
Natera Inc (NTRA) 財務データ
収益
当期純利益
現金流量
EPS
Natera Inc (NTRA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sheena Jonathan | CO-FOUNDER |
May 13 '26 |
Sale |
201.56 |
1,500 |
302,347 |
19,532 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
May 05 '26 |
Sale |
213.77 |
6,986 |
1,493,363 |
2,376,402 |
| Rabinowitz Matthew | EXECUTIVE CHAIRMAN |
May 04 '26 |
Sale |
206.16 |
722 |
148,848 |
2,382,440 |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER |
May 04 '26 |
Sale |
210.49 |
482 |
101,456 |
57,496 |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER |
May 01 '26 |
Sale |
206.16 |
313 |
64,528 |
57,978 |
| Sheena Jonathan | CO-FOUNDER |
May 01 '26 |
Sale |
206.16 |
107 |
22,059 |
255,652 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
May 01 '26 |
Sale |
203.69 |
3,405 |
693,560 |
142,295 |
| Fesko John | PRESIDENT, CHIEF BUS. OFFICER |
May 01 '26 |
Sale |
206.16 |
291 |
59,993 |
187,220 |
| Chapman Steven Leonard | CEO AND PRESIDENT |
May 01 '26 |
Sale |
206.16 |
902 |
185,956 |
149,867 |
| RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER |
May 01 '26 |
Sale |
206.16 |
330 |
68,033 |
222,694 |
0.91%
大文字化:
|
ボリューム (24 時間):